Long-term prediction of liver cancer risk in MASH patients
Part of Cancer, Digestive system clinical trials.
This study uses blood protein tests to predict the long-term risk of developing liver cancer in people with MASH, a type of fatty liver disease. It may help identify who needs closer monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You have had a liver biopsy that confirmed MASH (a fatty liver disease with inflammation and liver cell damage).
- You are not a heavy drinker, meaning women drink less than 20 grams of alcohol per day and men less than 30 grams per day.
- You do not have other causes of liver disease such as viral hepatitis, autoimmune disease, or drug-induced liver injury.
- You are not under legal guardianship or judicial protection.
- You agree to allow your data and biological samples to be used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This trial tests an experimental gene therapy (VV-14303) given as a single injection into the muscle to treat MASH, a common type of fatty liver disease with inflammation. The study will check if the treatment is safe and helps improve liver health.
This study looks at a possible link between MASH (liver inflammation with fat buildup) and tiny cell structures that help liver cells work. Researchers want to understand this better in people having weight-loss surgery, where a small liver sample will be taken.
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
Hear when a new MASH-related HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.